TWI628188B - 具有hiv成熟抑制活性之c-17及c-3經修飾之三萜類化合物 - Google Patents

具有hiv成熟抑制活性之c-17及c-3經修飾之三萜類化合物 Download PDF

Info

Publication number
TWI628188B
TWI628188B TW101103140A TW101103140A TWI628188B TW I628188 B TWI628188 B TW I628188B TW 101103140 A TW101103140 A TW 101103140A TW 101103140 A TW101103140 A TW 101103140A TW I628188 B TWI628188 B TW I628188B
Authority
TW
Taiwan
Prior art keywords
alkyl
group
substituted
compound
pentamethyl
Prior art date
Application number
TW101103140A
Other languages
English (en)
Chinese (zh)
Other versions
TW201309717A (zh
Inventor
藍恩 艾立西亞 里圭洛
Alicia Regueiro-Ren
劉崢
Zheng Liu
傑卡布 史威朵斯基
Jacob Swidorski
辛尼
Ny Sin
布萊恩 李 凡納伯
Brian Lee Venables
席辛元
Sing-Yuen Sit
陳彥
Yan Chen
陳潔
Jie Chen
尼可拉斯A 明威
Nicholas A. Meanwell
Original Assignee
英商Viiv醫療保健英國(No‧4)有限公司
ViiV Healthcare UK (No.4) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商Viiv醫療保健英國(No‧4)有限公司, ViiV Healthcare UK (No.4) Limited filed Critical 英商Viiv醫療保健英國(No‧4)有限公司
Publication of TW201309717A publication Critical patent/TW201309717A/zh
Application granted granted Critical
Publication of TWI628188B publication Critical patent/TWI628188B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW101103140A 2011-01-31 2012-01-31 具有hiv成熟抑制活性之c-17及c-3經修飾之三萜類化合物 TWI628188B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161437893P 2011-01-31 2011-01-31
US61/437,893 2011-01-31

Publications (2)

Publication Number Publication Date
TW201309717A TW201309717A (zh) 2013-03-01
TWI628188B true TWI628188B (zh) 2018-07-01

Family

ID=45567147

Family Applications (1)

Application Number Title Priority Date Filing Date
TW101103140A TWI628188B (zh) 2011-01-31 2012-01-31 具有hiv成熟抑制活性之c-17及c-3經修飾之三萜類化合物

Country Status (25)

Country Link
US (3) US8846647B2 (enExample)
EP (1) EP2670765B1 (enExample)
JP (1) JP6001560B2 (enExample)
KR (1) KR101886467B1 (enExample)
CN (1) CN103429607B (enExample)
AR (1) AR085053A1 (enExample)
AU (1) AU2012212509B2 (enExample)
BR (1) BR112013019419A2 (enExample)
CA (1) CA2826113C (enExample)
CL (1) CL2013002185A1 (enExample)
CO (1) CO6751275A2 (enExample)
EA (1) EA022470B1 (enExample)
ES (1) ES2653847T3 (enExample)
IL (1) IL227678B (enExample)
MA (1) MA34909B1 (enExample)
MY (1) MY162186A (enExample)
PE (1) PE20141152A1 (enExample)
PH (1) PH12013501528A1 (enExample)
PT (1) PT2670765T (enExample)
SG (1) SG192144A1 (enExample)
TN (1) TN2013000321A1 (enExample)
TW (1) TWI628188B (enExample)
UY (1) UY33886A (enExample)
WO (1) WO2012106190A1 (enExample)
ZA (1) ZA201306546B (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. C-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
HRP20171859T1 (hr) 2010-12-17 2018-01-26 Reata Pharmaceuticals, Inc. Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
HRP20151212T1 (hr) * 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
CA2829618C (en) 2011-03-11 2019-07-09 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
CA2849475A1 (en) 2011-09-21 2013-03-28 Bristol-Myers Squibb Company Novel betulinic acid derivatives with antiviral activity
US8906889B2 (en) * 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
DK3444261T3 (da) 2012-04-27 2021-03-08 Reata Pharmaceuticals Inc 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
US8889854B2 (en) * 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
WO2014027045A1 (en) * 2012-08-15 2014-02-20 Glaxo Group Limited Chemical process
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
EA027371B1 (ru) * 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
NZ724644A (en) 2014-04-11 2023-07-28 Viiv Healthcare Uk No 4 Ltd Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
EP3218387A1 (en) 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
BR112017009852A2 (pt) 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, usos de um composto
CN107428798A (zh) * 2015-04-14 2017-12-01 Viiv保健英国第四有限公司 生产hiv成熟抑制剂的方法
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
US20180194799A1 (en) 2015-07-28 2018-07-12 Glaxosmithkline Intellectual Property (No.2) Limited Betuin derivatives for preventing or treating hiv infections
WO2017025901A1 (en) * 2015-08-11 2017-02-16 Hetero Research Foundation Novel c28-analogues with c3-modifications of triterpene derivatives as hiv inhibitors
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
CN108368071A (zh) 2015-09-24 2018-08-03 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的化合物
TW201726133A (zh) 2015-11-20 2017-08-01 Viiv醫療保健英國(No‧4)有限公司 Hiv成熟抑制劑調配物
WO2017125870A1 (en) 2016-01-20 2017-07-27 Glaxosmithkline Intellectual Property (No.2) Limited Amine derivatives of lupanes with hiv maturation inhibitory activity
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3478703A1 (en) * 2016-06-30 2019-05-08 ViiV Healthcare UK (No.5) Limited Triterpenoid inhibitors of human immunodeficiency virus replication
WO2018044822A1 (en) * 2016-08-31 2018-03-08 Viiv Healthcare Company Combinations and uses and treatments thereof
MX2020001412A (es) 2017-08-04 2020-08-03 Ardelyx Inc Compuestos y métodos para tratar la hiperpotasemia.
JP6926939B2 (ja) * 2017-10-23 2021-08-25 東京エレクトロン株式会社 半導体装置の製造方法
JP6977474B2 (ja) * 2017-10-23 2021-12-08 東京エレクトロン株式会社 半導体装置の製造方法
US20210347813A1 (en) 2018-04-24 2021-11-11 Viiv Healthcare Uk (No. 5) Limited Compounds with hiv maturation inhibitory activity
PL237998B1 (pl) 2018-05-28 2021-06-28 Narodowy Inst Lekow Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
ES3039169T3 (en) 2019-02-07 2025-10-17 Ardelyx Inc Glycyrrhetinic acid derivatives for use in treating hyperkalemia
PL3924361T3 (pl) 2019-02-11 2024-03-18 Hetero Labs Limited Nowe pochodne triterpenu jako inhibitory wirusa hiv
KR102891865B1 (ko) 2019-07-19 2025-11-26 리아타 파마슈티컬즈, 아이엔씨. C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
GB2598300A (en) * 2020-08-21 2022-03-02 Univ Durham Cross-linking method and applications in bioconjugation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015196A1 (en) * 2009-07-14 2011-01-20 Hetero Research Foundation Lupeol-type triterpene derivatives as antivirals

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
MXPA06010592A (es) 2004-03-17 2007-06-12 Panacos Pharmaceuticals Inc Sales farmaceuticas de acido 3-o-(3',3'-dimetilsuccinil) betulinico.
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
US8067620B2 (en) 2005-05-04 2011-11-29 Medicines For Malaria Venture Mmv Dispiro 1,2,4-trioxolane antimalarials
WO2008127364A2 (en) * 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
BR112012030818A2 (pt) * 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
WO2011153319A1 (en) * 2010-06-04 2011-12-08 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110015196A1 (en) * 2009-07-14 2011-01-20 Hetero Research Foundation Lupeol-type triterpene derivatives as antivirals

Also Published As

Publication number Publication date
SG192144A1 (en) 2013-08-30
IL227678B (en) 2018-04-30
AU2012212509A1 (en) 2013-09-19
US20130035318A1 (en) 2013-02-07
BR112013019419A2 (pt) 2019-12-03
PH12013501528A1 (en) 2013-09-16
US20140343000A1 (en) 2014-11-20
KR101886467B1 (ko) 2018-08-07
JP2014503595A (ja) 2014-02-13
IL227678A0 (en) 2013-09-30
CA2826113C (en) 2018-09-04
PE20141152A1 (es) 2014-09-22
CA2826113A1 (en) 2012-08-09
AR085053A1 (es) 2013-08-07
US8846647B2 (en) 2014-09-30
MA34909B1 (fr) 2014-02-01
EA201391127A1 (ru) 2013-12-30
CO6751275A2 (es) 2013-09-16
PT2670765T (pt) 2018-01-08
AU2012212509B2 (en) 2016-01-21
KR20140016279A (ko) 2014-02-07
CN103429607B (zh) 2016-02-17
NZ614871A (en) 2014-06-27
EP2670765B1 (en) 2017-10-18
MY162186A (en) 2017-05-31
ES2653847T3 (es) 2018-02-09
JP6001560B2 (ja) 2016-10-05
US20160151387A1 (en) 2016-06-02
WO2012106190A1 (en) 2012-08-09
ZA201306546B (en) 2015-03-25
CL2013002185A1 (es) 2013-12-27
CN103429607A (zh) 2013-12-04
EA022470B1 (ru) 2016-01-29
TW201309717A (zh) 2013-03-01
EP2670765A1 (en) 2013-12-11
TN2013000321A1 (en) 2015-01-20
UY33886A (es) 2012-07-31

Similar Documents

Publication Publication Date Title
CN103429607B (zh) 具有hiv成熟抑制活性的c-17和c-3经修饰的三萜系化合物
JP6155285B2 (ja) Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド
JP6186010B2 (ja) Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類
JP5755731B2 (ja) Hiv成熟阻害剤としての修飾c−3ベツリン酸誘導体のc−28アミド
CA2944778C (en) Triterpenoids with hiv maturation inhibitory activity
ES2957767T3 (es) Triterpenoides modificados en C-3 y C-17 como inhibidores del VIH-1
NZ614871B2 (en) C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees